<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK26372" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK26372/" /><meta name="ncbi_pagename" content="Glycogen Storage Disease Type III - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Glycogen Storage Disease Type III - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Glycogen Storage Disease Type III" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/12/29" /><meta name="citation_author" content="Aditi Dagli" /><meta name="citation_author" content="Christiaan P Sentner" /><meta name="citation_author" content="David A Weinstein" /><meta name="citation_pmid" content="20301788" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK26372/" /><meta name="citation_keywords" content="Cori Disease" /><meta name="citation_keywords" content="Debrancher Deficiency" /><meta name="citation_keywords" content="Forbes Disease" /><meta name="citation_keywords" content="GSD III" /><meta name="citation_keywords" content="Cori Disease" /><meta name="citation_keywords" content="Debrancher Deficiency" /><meta name="citation_keywords" content="GSD III" /><meta name="citation_keywords" content="Forbes Disease" /><meta name="citation_keywords" content="Glycogen debranching enzyme" /><meta name="citation_keywords" content="AGL" /><meta name="citation_keywords" content="Glycogen Storage Disease Type III" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Glycogen Storage Disease Type III" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Aditi Dagli" /><meta name="DC.Contributor" content="Christiaan P Sentner" /><meta name="DC.Contributor" content="David A Weinstein" /><meta name="DC.Date" content="2016/12/29" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK26372/" /><meta name="description" content="Glycogen storage disease type III (GSD III) is characterized by variable liver, cardiac muscle, and skeletal muscle involvement." /><meta name="og:title" content="Glycogen Storage Disease Type III" /><meta name="og:type" content="book" /><meta name="og:description" content="Glycogen storage disease type III (GSD III) is characterized by variable liver, cardiac muscle, and skeletal muscle involvement." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK26372/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/gsd3/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK26372/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8ADE04DFC88231000000000443022B.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK26372_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK26372_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/gsd1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/gsd4/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK26372_"><span class="title" itemprop="name">Glycogen Storage Disease Type III</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Cori Disease, Debrancher Deficiency, Forbes Disease, GSD III</div><p class="contrib-group"><span itemprop="author">Aditi Dagli</span>, MD, <span itemprop="author">Christiaan P Sentner</span>, MD, and <span itemprop="author">David A Weinstein</span>, MD, MMSc.</p><a data-jig="ncbitoggler" href="#__NBK26372_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK26372_ai__"><div class="contrib half_rhythm"><span itemprop="author">Aditi Dagli</span>, MD<div class="affiliation small">Glycogen Storage Disease Program<br />University of Florida College of Medicine<br />Gainesville, Florida</div><div class="affiliation small">Florida Hospital Medical Group<br />Orlando, Florida<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@ilgaditida" class="oemail">moc.liamg@ilgaditida</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christiaan P Sentner</span>, MD<div class="affiliation small">Department of Metabolic Diseases<br />Beatrix Children's Hospital<br />University Medical Center Groningen<br />Groningen, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@rentnes" class="oemail">moc.liamg@rentnes</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">David A Weinstein</span>, MD, MMSc<div class="affiliation small">University of Connecticut;<br />Connecticut Children&#x02019;s Medical Center<br />Hartford, Connecticut<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.chcu@nietsniew" class="oemail">ude.chcu@nietsniew</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 9, 2010</span>; Last Update: <span itemprop="dateModified">December 29, 2016</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="gsd3.Summary" itemprop="description"><h2 id="_gsd3_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Glycogen storage disease type III (GSD III) is characterized by variable liver, cardiac muscle, and skeletal muscle involvement.</p><p>GSD IIIa is the most common subtype, present in about 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; it manifests with liver and muscle involvement. GSD IIIb, with liver involvement only, comprises about 15% of all GSD III.</p><p>In infancy and early childhood, liver involvement presents as ketotic hypoglycemia, hepatomegaly, hyperlipidemia, and elevated hepatic transaminases. In adolescence and adulthood, liver disease becomes less prominent. Hypertrophic cardiomyopathy develops in the majority of those with GSD IIIa, usually during childhood. Its clinical significance ranges from asymptomatic in the majority to severe cardiac dysfunction, congestive heart failure, and (rarely) sudden death. Skeletal myopathy manifesting as weakness is not usually evident in childhood, but slowly progresses, typically becoming prominent in the third to fourth decade.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Hepatomegaly, ketotic hypoglycemia with fasting, and elevated serum concentrations of transaminases and CK are the hallmarks of GSD III. The serum CK may not be elevated at the time of the diagnostic work up, but the absence of lactic acidosis and markedly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations may provide clues to the diagnosis. Measurement of fasting serum concentration of glucose after glucagon administration can be used to support the diagnosis; glucagon administration should not cause the glucose concentration to rise following a prolonged fast, but should do so after a fast of two hours or less. The diagnosis is established by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>AGL</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> A high-protein diet and frequent feeds (every 3-4 hours) to maintain euglycemia is the mainstay of management in infancy. Fructose and galactose can be used; special formulas are not required. Toward the end of the first year of life, one to three daily doses of 1 g/kg cornstarch can be used to avoid hypoglycemia. A protein intake of 3 g/kg is recommended. For those who cannot make it through the night on cornstarch and protein, Glycosade<sup>&#x000ae;</sup> extended-release cornstarch can be used. Liver transplantation is reserved for those with severe hepatic cirrhosis, liver dysfunction, and/or hepatocellular carcinoma. Liver transplantation may exacerbate myopathy and cardiomyopathy.</p><p><i>Prevention of primary manifestations:</i> See <i>Treatment of manifestations</i>.</p><p><i>Prevention of secondary complications:</i> Special precautions for persons undergoing surgery to avoid hypoglycemia.</p><p><i>Surveillance:</i> To identify periods of suboptimal metabolic control, blood glucose should be measured between 2 AM and 4 AM or urine ketones should be measured upon awakening at least several times per month. Annual: measurement of height and weight; liver ultrasound examination; laboratory studies (LFTs, CK, lipid profile); and echocardiogram. A bone density determination is recommended after growth is complete.</p><p><i>Agents/circumstances to avoid:</i> High simple sugar intake, steroid-based drugs, growth hormone replacement. Use with caution: hormonal contraceptives and statins for control of hyperlipidemia.</p><p><i>Evaluation of relatives at risk:</i> Diagnosis of at-risk sibs at birth allows for early dietary intervention to prevent hypoglycemia.</p><p><i>Pregnancy management</i>: Increased monitoring and support during pregnancy of women with GSD III because of increasing glucose needs during the course of pregnancy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>GSD III is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for pregnancies at increased risk are possible if the pathogenic variants have been identified in the family.</p></div></div><div id="gsd3.Diagnosis"><h2 id="_gsd3_Diagnosis_">Diagnosis</h2><p>Glycogen storage disease type III (GSD III) is characterized by variable liver, cardiac muscle, and skeletal muscle involvement.</p><p>Four subtypes of GSD type III, based on differences in tissue expression of the deficient enzyme [<a class="bk_pop" href="#gsd3.REF.endo.2006.958">Endo et al 2006</a>], are recognized:</p><ul><li class="half_rhythm"><div>GSD IIIa (~85% of all GSD III). Liver and muscle involvement, presumably resulting from enzyme deficiency in both liver and muscle</div></li><li class="half_rhythm"><div>GSD IIIb (~15% of all GSD III). Only liver involvement, presumably resulting from enzyme deficiency in liver only</div></li><li class="half_rhythm"><div>GSD IIIc (extremely rare). Presumably the result of deficiency of only glucosidase debranching activity</div></li><li class="half_rhythm"><div>GSD IIId (extremely rare). Presumably the result of deficiency of only transferase debranching activity</div></li></ul><div id="gsd3.Suggestive_Findings"><h3>Suggestive Findings</h3><p>GSD III <b>should be suspected</b> in individuals with the following cardinal clinical features of GSD IIIa and GSD IIIb and preliminary laboratory findings.</p><div id="gsd3.Cardinal_Clinical_Features"><h4>Cardinal Clinical Features</h4><p><b>Liver disease</b></p><ul><li class="half_rhythm"><div><b>In infancy and early childhood</b>, cardinal features are related to liver involvement: ketotic hypoglycemia, hepatomegaly, hyperlipidemia, and elevated hepatic transaminases. Hepatomegaly becomes evident early in infancy and may be the presenting feature. The liver is firm and may be markedly enlarged on clinical examination.</div></li><li class="half_rhythm"><div><b>In adolescence and adulthood</b>, the liver manifestations become less prominent, possibly due to progressing hepatic fibrosis and decreased glucose demands. However, hepatic cirrhosis and adenomas are seen in a small percentage of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li></ul><p><b>Myopathy</b> presenting as weakness progresses slowly and becomes prominent in the third to fourth decade of life [<a class="bk_pop" href="#gsd3.REF.lucchiari.2007.72">Lucchiari et al 2007</a>].</p><p><b>Hypertrophic cardiomyopathy</b> develops in the majority of people with GSD IIIa usually during childhood (and in rare cases as early as the first year of life); skeletal myopathy is absent or minimal. Its clinical significance varies as most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are asymptomatic [<a class="bk_pop" href="#gsd3.REF.lee.1997.834">Lee et al 1997</a>]; however, severe cardiac dysfunction, congestive heart failure, and (rarely) sudden death have been reported.</p></div></div><div id="gsd3.Preliminary_Laboratory_Findings"><h3>Preliminary Laboratory Findings</h3><p><b>Ketotic hypoglycemia</b> with fasting is a prominent feature of GSD III. However, non-ketotic hypoglycemia has been reported [<a class="bk_pop" href="#gsd3.REF.seigel.2008.587">Seigel et al 2008</a>]. Ketone concentrations of 0.5-1.5 mmol/L after an overnight fast can be seen in the untreated state; they resolve when hypoglycemia is prevented.</p><p><b>Serum concentrations</b></p><ul><li class="half_rhythm"><div>Creatine kinase (CK) is elevated once toddlers become active; however, a normal CK in the first few years of life does not exclude muscle involvement. Likewise, <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> CK elevation without clinical evidence of myopathy or muscle weakness is common in the first two decades of life [<a class="bk_pop" href="#gsd3.REF.chen.2001">Chen 2001</a>].</div></li><li class="half_rhythm"><div>Triglycerides, cholesterol, and liver transaminases are elevated in the untreated state:</div><ul><li class="half_rhythm"><div>Serum concentrations of triglycerides of 200-500 mg/dL and occasionally up to 4000 mg/dL have been noted. With treatment, the triglycerides normalize, but they may also be elevated in the treated state when metabolic control is suboptimal.</div></li><li class="half_rhythm"><div>Liver transaminases in GSD III are highest among all the glycogen storage diseases; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are usually higher than 500 U/L and often higher than 1000 U/L.</div></li></ul></li><li class="half_rhythm"><div>Uric acid and lactic acid are usually normal [<a class="bk_pop" href="#gsd3.REF.chen.2001">Chen 2001</a>, <a class="bk_pop" href="#gsd3.REF.wolfsdorf.2003.95">Wolfsdorf &#x00026; Weinstein 2003</a>].</div></li></ul></div><div id="gsd3.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>Hepatomegaly and ketotic hypoglycemia in the setting of elevated serum concentrations of transaminases and CK are the hallmarks of GSD III.</p><p>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>AGL</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is the next step in confirming the diagnosis:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> is performed first (see <a class="figpopup" href="/books/NBK26372/table/gsd3.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figgsd3Tmoleculargenetictestingusedin" rid-ob="figobgsd3Tmoleculargenetictestingusedin">Table 1</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>AGL</i> and other genes of interest (see <a href="#gsd3.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p>If <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> cannot establish a diagnosis, analysis of debranching enzyme activity in either liver or muscle can be considered (see <b>Analysis of debranching enzyme activity</b>).</p><div id="gsd3.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Glycogen Storage Disease Type III</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26372/table/gsd3.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__gsd3.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>AGL</i></td><td headers="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2</sup></td><td headers="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95%&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_gsd3.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="gsd3.TF.1.1"><p class="no_margin">See <a href="/books/NBK26372/#gsd3.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="gsd3.TF.1.2"><p class="no_margin">See <a href="#gsd3.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="gsd3.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="gsd3.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#gsd3.REF.goldstein.2010.424">Goldstein et al [2010]</a>, <a class="bk_pop" href="#gsd3.REF.sentner.2016.697">Sentner et al [2016]</a>.</p></div></dd><dt>5. </dt><dd><div id="gsd3.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="gsd3.TF.1.6"><p class="no_margin">Exon <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>(s) or complex rearrangements have been reported [<a class="bk_pop" href="#gsd3.REF.endo.2009.1233">Endo et al 2009</a>, <a class="bk_pop" href="#gsd3.REF.goldstein.2010.424">Goldstein et al 2010</a>, <a class="bk_pop" href="#gsd3.REF.lu.2016.641">Lu et al 2016</a>].</p></div></dd></dl></div></div></div><p><b>Analysis of debranching enzyme activity.</b> The debranching enzyme is a single polypeptide with two catalytic sites, amylo-1,6-glucosidase (EC 3.2.1.33) and 4-alpha-glucanotransferase (EC 2.4.1.25). Because liver or muscle biopsy is not required to make the diagnosis of GSD III, they are rarely performed. However, if <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is inconclusive, debranching enzyme activity can be measured in either liver or muscle biopsy specimens and compared to controls.</p><p>Note: (1) Analysis of debranching enzyme activity in white blood cells is not available in the United States. (2) To distinguish GSD IIIa (liver and muscle involvement; 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) from GSD IIIb (liver only; 15% of affected individuals), muscle biopsy may be considered to measure debranching enzyme activity and glycogen content since normal serum CK concentrations do not preclude muscle involvement, and information on <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> is insufficient for clinical subtyping.</p></div></div><div id="gsd3.Clinical_Characteristics"><h2 id="_gsd3_Clinical_Characteristics_">Clinical Characteristics</h2><div id="gsd3.Clinical_Description"><h3>Clinical Description</h3><p>Glycogen storage disease type III (GSD III) is characterized by variable liver, skeletal muscle, and cardiac muscle involvement. GSD IIIa (~85% of all GSD III), characterized by liver and muscle involvement, and GSD IIIb (~15% of all GSD III), characterized by only liver involvement, typically present in childhood with hepatomegaly and ketotic hypoglycemia with markedly elevated liver transaminases and hypertriglyceridemia.</p><p><b>Liver disease.</b> The spectrum of presentation may include severe hypoglycemia as seen in <a href="/books/n/gene/gsd1/">GSD I</a> or asymptomatic hepatomegaly. Liver disease is progressive, resulting in liver fibrosis and in some cases cirrhosis and hepatocellular carcinoma [<a class="bk_pop" href="#gsd3.REF.siciliano.2000.80">Siciliano et al 2000</a>, <a class="bk_pop" href="#gsd3.REF.cosme.2005.622">Cosme et al 2005</a>, <a class="bk_pop" href="#gsd3.REF.demo.2007.492">Demo et al 2007</a>, <a class="bk_pop" href="#gsd3.REF.lucchiari.2007.72">Lucchiari et al 2007</a>].</p><p>Liver histology shows prominent distension of hepatocytes by glycogen; fibrous septa and periportal fibrosis are frequently present. Fibrosis increases during the course of the disease, and is typically greater in GSD III than in the other forms of GSD (<a href="#gsd3.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>Elevated prothrombin time and low serum concentration of albumin are noted in those with GSD III who develop cirrhosis [<a class="bk_pop" href="#gsd3.REF.demo.2007.492">Demo et al 2007</a>].</p><p>Hepatic adenomas have been observed in small cohorts in as many as 25% of individuals with GSD III. However, the true prevalence is thought to be less; more recently <a class="bk_pop" href="#gsd3.REF.sentner.2016.697">Sentner et al [2016]</a> showed a prevalence of 6.9%. The relationship between metabolic control and formation of adenomas has not been elucidated.</p><p>In GSD III, hepatic cirrhosis &#x02013; not adenomas &#x02212; leads to hepatocellular carcinoma [<a class="bk_pop" href="#gsd3.REF.demo.2007.492">Demo et al 2007</a>]. In contrast, in <a href="/books/n/gene/gsd1/">GSD I</a> hepatocellular carcinoma develops in existing adenomas.</p><p><b>Myopathy</b> is absent or minimal in childhood and progresses slowly, becoming prominent in the third to fourth decade of life. Proximal muscles are primarily affected but involvement of distal muscles (including the calves, peroneal muscles [<a class="bk_pop" href="#gsd3.REF.lucchiari.2007.72">Lucchiari et al 2007</a>], and hands) is also seen.</p><p>Altered perfusion [<a class="bk_pop" href="#gsd3.REF.wary.2010.548">Wary et al 2010</a>] and nerve dysfunction may contribute to exercise intolerance and muscle weakness [<a class="bk_pop" href="#gsd3.REF.hobsonwebb.2010.440">Hobson-Webb et al 2010</a>], respectively.</p><p><b>Cardiomyopathy</b> with an echocardiographic appearance of hypertrophic cardiomyopathy occurs in the majority of individuals with GSD IIIa. Most recently cardiac involvement was reported in 58% of persons with GSD IIIa included in the worldwide type III database [<a class="bk_pop" href="#gsd3.REF.sentner.2016.697">Sentner et al 2016</a>].</p><p>Cardiomyopathy usually appears during childhood; however, rarely it has been documented in the first year of life. Its clinical significance is uncertain as most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are asymptomatic; however, severe cardiac dysfunction, congestive heart failure, and sudden death have occasionally been reported.</p><p><b>Growth</b> may be compromised by poor metabolic control. Catch-up growth may be observed with the establishment of good metabolic control.</p><p><b>Osteoporosis and osteopenia</b> have been noted in GSD III as in other glycogen storage diseases. <a class="bk_pop" href="#gsd3.REF.mundy.2008.418">Mundy et al [2008]</a> suggested that the cause of the osteoporosis is probably <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a> with muscle weakness, abnormal metabolic environment, and suboptimal nutrition playing roles in pathogenesis. <a class="bk_pop" href="#gsd3.REF.melis.2016.79">Melis et al [2016]</a> also hypothesized a multifactorial causation due to metabolic imbalance stemming from chronic hyperlipidemia and reduced serum levels of IGF-1, insulin, and osteocalcin.</p><p><b>Polycystic ovary disease</b> may be seen in GSD III; fertility does not appear to be affected [<a class="bk_pop" href="#gsd3.REF.chen.2001">Chen 2001</a>].</p></div><div id="gsd3.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>There is a clear <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation with at least two pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 (<a class="figpopup" href="/books/NBK26372/table/gsd3.T.selected_agl_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figgsd3Tselectedaglpathogenicvariants" rid-ob="figobgsd3Tselectedaglpathogenicvariants">c.17_18delAG</a> and <a class="figpopup" href="/books/NBK26372/table/gsd3.T.selected_agl_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figgsd3Tselectedaglpathogenicvariants" rid-ob="figobgsd3Tselectedaglpathogenicvariants">c.16C&#x0003e;T</a>) associated with GSD IIIb. It is unclear, however, what mechanism enables individuals with pathogenic variants in exon 3 to retain debranching enzyme activity in muscle tissue. A possible explanation was proposed by <a class="bk_pop" href="#gsd3.REF.goldstein.2010.424">Goldstein et al [2010]</a> in which the exon 3 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is bypassed using a downstream start codon, thus creating a fully functioning isoform without the exon 3 pathogenic variants.</p><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> between other <i>AGL</i> pathogenic variants and disease severity have been reported. Heterogeneity even within a given family has been noted [<a class="bk_pop" href="#gsd3.REF.lucchiari.2007.72">Lucchiari et al 2007</a>].</p></div><div id="gsd3.Nomenclature"><h3>Nomenclature</h3><p>Abnormal glycogen with short outer chains was first recognized by <a class="bk_pop" href="#gsd3.REF.illingworth.1952.653">Illingworth &#x00026; Cori [1952]</a> in a patient of Dr. GB Forbes. Hence, GSD III is also known as limit dextrinosis, Cori disease, and Forbes disease.</p></div><div id="gsd3.Prevalence"><h3>Prevalence</h3><p>GSD III is rare, with an incidence of 1:100,000.</p><p>Certain populations have high prevalence as the result of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>, including:</p><ul><li class="half_rhythm"><div>The Inuit population in Nunavik (Canada) (~1:2500) [<a class="bk_pop" href="#gsd3.REF.rousseaunepton.2015.e68">Rousseau-Nepton et al 2015</a>];</div></li><li class="half_rhythm"><div>The Faroese (~1:3100) [<a class="bk_pop" href="#gsd3.REF.santer.2001.388">Santer et al 2001</a>];</div></li><li class="half_rhythm"><div>North African Jews from Israel (~1:5400) [<a class="bk_pop" href="#gsd3.REF.parvari.1997.266">Parvari et al 1997</a>].</div></li></ul></div></div><div id="gsd3.Genetically_Related_Allelic_Disorde"><h2 id="_gsd3_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>AGL</i>.</p></div><div id="gsd3.Differential_Diagnosis"><h2 id="_gsd3_Differential_Diagnosis_">Differential Diagnosis</h2><p>Findings in GSD III that may help distinguish it from other forms of GSD include the following:</p><ul><li class="half_rhythm"><div>A history of hypoglycemia and hepatomegaly in childhood.</div></li><li class="half_rhythm"><div>Elevated serum CK concentrations in the setting of a hepatic glycogen storage disease in a young child.</div></li><li class="half_rhythm"><div>Remarkably elevated serum transaminases often in the 1000 range prior to commencement of treatment. No other GSD is associated with such marked elevation of AST and ALT [<a class="bk_pop" href="#gsd3.REF.chen.2001">Chen 2001</a>, <a class="bk_pop" href="#gsd3.REF.wolfsdorf.2003.95">Wolfsdorf &#x00026; Weinstein 2003</a>].</div></li><li class="half_rhythm"><div>Liver histology. Fibrosis increases over time in GSD III and is typically greater than in the other forms of GSD: fibrosis is not a feature of <a href="/books/n/gene/gsd1/">GSD I</a>, and steatosis is less than that seen in GSD I; fibrosis can also be seen in <a href="/books/n/gene/gsd4/">GSD IV</a> and less prominent fibrosis occurs in <a href="/books/n/gene/gsd9/">GSD IX</a>.</div></li></ul><p><a href="/books/n/gene/gsd1/"><b>Glycogen storage disease type I</b></a>
<b>(GSD I),</b> caused by mutation of <i>G6PC</i> (GSD Ia) or <i>SLC37A4</i> (GSD Ib), is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. GSD III may be indistinguishable from GSD I in infancy. However, some important differences may help distinguish the two.</p><ul><li class="half_rhythm"><div>GSD III does not usually have the elevations in uric acid and lactic acid seen in GSD I.</div></li><li class="half_rhythm"><div>In contrast to GSD I, ketotic hypoglycemia is seen in GSD III, and ketones are grossly elevated in morning urine samples of untreated individuals.</div></li><li class="half_rhythm"><div>Hypoglycemia and hypertriglyceridemia are more severe in GSD I than in GSD III.</div></li></ul><p><a href="/books/n/gene/gsd6/"><b>Glycogen storage disease type VI</b></a>
<b>(GSD VI) and</b>
<a href="/books/n/gene/gsd9/"><b>type IX</b></a>
<b>(GSD IX)</b> are caused by a deficiency of hepatic glycogen phosphorylase and phosphorylase kinase, respectively. Phosphorylase kinase is responsible for activation of hepatic glycogen phosphorylase that cleaves the terminal glucose moieties from the glycogen chain. The phenotypes of GSD VI and GSD IX are clinically indistinguishable. Affected individuals present with ketotic hypoglycemia and hepatomegaly. They do not have elevated serum concentrations of CK, and AST and ALT are usually not as high as in GSD III.</p><p>GSD VI, caused by mutation of <i>PYGL</i>, is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p>GSD IX, caused by mutation of genes encoding phosphorylase kinase, can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><b>Other muscle forms of GSD</b> including <a href="/books/n/gene/gsd5/">GSD V</a> and VII present with muscle weakness and rhabdomyolysis in adulthood.</p></div><div id="gsd3.Management"><h2 id="_gsd3_Management_">Management</h2><div id="gsd3.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with glycogen storage disease type III (GSD III), the following are recommended:</p><ul><li class="half_rhythm"><div>Liver ultrasound examination to determine the size of the liver and to identify adenomas if present</div></li><li class="half_rhythm"><div>Baseline electrocardiogram and echocardiogram</div></li><li class="half_rhythm"><div>Consultation with a biochemical geneticist</div></li></ul></div><div id="gsd3.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The mainstay of management of GSD III is a high-protein diet with cornstarch supplementation to maintain euglycemia.</p><p>In infancy, feeds every three to four hours are recommended. Unlike the diet used to treat infants with <a href="/books/n/gene/gsd1/">GSD I</a>, the diet used to treat infants with GSD III can include fructose and galactose, as individuals with GSD III can utilize these sugars; special formulas are not required.</p><p>Toward the end of the first year of life, cornstarch is tolerated and can be used to prevent hypoglycemia. Initially one to three doses per day may be required with typical starting dose of 1 g/kg every six hours. The doses can be titrated based on the results of glucose and ketone monitoring.</p><p>A protein intake of 3 g/kg is recommended as gluconeogenesis is intact and protein can be used as a source of glucose. For those who cannot make it through the night on cornstarch and protein, Glycosade<sup>&#x000ae;</sup> extended-release cornstarch can be used [<a class="bk_pop" href="#gsd3.REF.ross.2015.137">Ross et al 2015</a>].</p><p>A high-protein diet prevents breakdown of endogenous muscle protein in times of glucose need and preserves skeletal and cardiac muscles.</p><p>Periods of suboptimal metabolic control can be identified by measuring blood glucose and blood ketone several times per month.</p><ul><li class="half_rhythm"><div>Although hypoglycemia upon awakening is uncommon in older children and adults since counter-regulation can raise blood glucose concentrations, monitoring blood glucose concentrations between 2 to 4 AM can reveal periods of suboptimal control.</div></li><li class="half_rhythm"><div>Elevated ketones reflect poor metabolic control as ketones are produced when glucose is unavailable and instead fatty acid oxidation is used as a source of energy. Monitoring blood ketones upon awakening at least several times per month using a portable blood ketone meter is recommended; the goal is to maintain blood beta-OH-butyrate concentrations in the normal range (&#x0003c;0.3 mmol/L). Additionally, morning urine ketone measurements can be monitored with regular urine dipsticks to give an overview of overnight metabolic control.</div></li></ul><p>Existing skeletal and cardiac myopathies can be improved with high-protein diet and avoidance of excessive carbohydrate intake [<a class="bk_pop" href="#gsd3.REF.slonim.1982.420">Slonim et al 1982</a>, <a class="bk_pop" href="#gsd3.REF.slonim.1984.906">Slonim et al 1984</a>, <a class="bk_pop" href="#gsd3.REF.dagli.2009.s103">Dagli et al 2009</a>, <a class="bk_pop" href="#gsd3.REF.valayannopoulos.2011.638">Valayannopoulos et al 2011</a>, <a class="bk_pop" href="#gsd3.REF.sentner.2012.13">Sentner et al 2012</a>].</p><p>Titration of protein and cornstarch in the diet is the primary treatment for elevated cholesterol and triglyceride concentrations, which usually result from suboptimal metabolic control.</p><p><b>Emergency protocol.</b> An emergency protocol to avoid dangerous hypoglycemia should be established. An intravenous (IV) infusion of 10% dextrose with 0.5 normal saline administered at 1.5 times the maintenance rate should be given immediately on admission to the emergency room. Serum concentrations of electrolytes, glucose, and ketones should be monitored. Efforts should be made to correct ketosis as it can induce vomiting and worsen the catabolic state.</p><p><b>Liver transplantation.</b> In GSD III hepatic complications are not the main cause of morbidity. Also, modern treatment strategies and good metabolic control can prevent major complications. Liver transplantation should therefore be viewed as a treatment of last resort for individuals with GSD III. Liver transplantation will prevent hypoglycemia in both GSD IIIa and GSD IIIb; the muscular defect, however, will remain present in individuals with GSD IIIa.</p><p>Because liver transplantation does not cure the heart and muscle problems and because transplantation has been associated with worsening myopathy and cardiomyopathy, liver transplantation is only indicated in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with severe hepatic cirrhosis, liver dysfunction, and/or hepatocellular carcinoma [<a class="bk_pop" href="#gsd3.REF.davis.2008.137">Davis &#x00026; Weinstein 2008</a>].</p></div><div id="gsd3.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Most of the primary manifestations of GSD III can be diminished or avoided with good metabolic (dietary) control.</p><p>When euglycemia is maintained and ketosis is avoided, hepatomegaly regresses and other abnormal laboratory values (e.g., elevated AST and ALT, increased serum concentration of triglycerides) normalize or come close to baseline [<a class="bk_pop" href="#gsd3.REF.bernier.2008.729">Bernier et al 2008</a>].</p><p>Myopathy and cardiomyopathy may be partially avoided by good dietary control. New evidence suggests that skeletal muscle metabolism is impaired during exercise in GSD III. Consumption of fructose or sucrose prior to exercise may improve exercise tolerance, but does not completely prevent exercise-induced damage [<a class="bk_pop" href="#gsd3.REF.preisler.2015.1767">Preisler et al 2015</a>].</p></div><div id="gsd3.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p><b>Surgery.</b> Persons with GSD III undergoing surgery should be admitted the night before the procedure and an IV infusion containing 10% dextrose started within two hours of the last cornstarch dose or the last meal. Glucose and ketone monitoring should continue overnight and during the procedure. IV dextrose infusion should not be stopped abruptly as dangerous hypoglycemia can occur from a hyperinsulinemic state. IV fluids need to be tapered slowly once optimal oral intake has been established and tolerated.</p><p><b>Osteoporosis</b> may occur in adults with GSD III. Good metabolic control leads to improved muscle strength and decreased ketosis. Bone mineralization is adversely affected in acidic environments. In contrast, improved muscle condition and strength increase bone mineralization. Supplementation with vitamin D and calcium is also recommended to augment bone mineralization.</p></div><div id="gsd3.Surveillance"><h3>Surveillance</h3><p>To identify periods of suboptimal metabolic control, blood glucose should be measured between 2 AM and 4 AM or urine ketones should be measured upon awakening at least several times per month.</p><ul><li class="half_rhythm"><div>Hypoglycemia is uncommon in older children and adults upon awakening since counter-regulation can raise blood glucose concentrations; however, monitoring blood glucose concentrations at 2 to 4 AM can reveal periods of suboptimal control.</div></li><li class="half_rhythm"><div>Monitoring of blood ketones upon awakening at least several times per month using a portable blood ketone meter is recommended. The goal is to maintain blood beta-OH-butyrate concentrations less than 0.3 mmol/L. Alternatively morning urine ketone measurements may be assessed with regular urine dipsticks to give an overview of overnight metabolic control.</div></li></ul><p>The following are appropriate annually:</p><ul><li class="half_rhythm"><div>Measurement of height and weight to monitor growth</div></li><li class="half_rhythm"><div>Liver ultrasound examination to screen for adenomas and evidence of liver scarring. MRI scans are limited to those individuals with abnormalities on the primary ultrasound screen.</div></li><li class="half_rhythm"><div>Laboratory studies: LFTs, CK, lipid profile</div></li><li class="half_rhythm"><div>Echocardiogram to monitor for cardiomyopathy; ECG</div></li></ul><p>Bone density measurements are recommended after growth is complete.</p></div><div id="gsd3.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>High sugar intake as excess sugar is stored as glycogen, which cannot be broken down</div></li><li class="half_rhythm"><div>Steroid-based drugs as they interfere with glucose metabolism and utilization. Long-term steroid usage itself can cause muscle weakness.</div></li><li class="half_rhythm"><div>Growth hormone replacement therapy as it interferes with glucose metabolism, worsens ketosis, and may theoretically cause liver adenomas to grow</div></li></ul><p>Use the following with caution:</p><ul><li class="half_rhythm"><div>Hormonal contraceptives in women as they can cause hepatic adenoma formation</div></li><li class="half_rhythm"><div>Statins for control of hyperlipidemia. Use of statins requires CK monitoring because of the potential of exacerbating the muscle disease of GSD IIIa.</div></li><li class="half_rhythm"><div>Beta blockers as they can induce hypoglycemia</div></li></ul></div><div id="gsd3.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Diagnosis of at-risk sibs at birth allows for early dietary intervention to prevent development of hypoglycemia associated with GSD III.</p><ul><li class="half_rhythm"><div>If the <i>AGL</i> pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is the best way to determine the genetic status of an at-risk sib.</div></li><li class="half_rhythm"><div>If the <i>AGL</i> pathogenic variants in the family are not known, diagnosis can be established by presence of fasting ketotic hypoglycemia.</div></li></ul><p>See <a href="#gsd3.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="gsd3.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Increased monitoring and support are required in pregnancy of women with GSD III as glucose needs will increase. The metabolic requirements will gradually increase throughout the second and third trimesters, and close monitoring of both glucose and ketones is critical to ensure optimal metabolic control. In the third trimester and close to term, it is imperative to maintain ketones within normal levels as ketosis can precipitate uterine contractions and preterm labor. During labor and in the postnatal period, intravenous glucose supplementation must be available at all times to prevent hypoglycemic episodes.</p></div><div id="gsd3.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="gsd3.Genetic_Counseling"><h2 id="_gsd3_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="gsd3.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Glycogen storage disease type III (GSD III) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="gsd3.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>AGL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with GSD III are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AGL</i>.</div></li><li class="half_rhythm"><div>If the reproductive partner of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> person is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, the offspring are at 50% risk of being affected.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>AGL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="gsd3.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>AGL</i> pathogenic variants in the family.</p></div><div id="gsd3.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#gsd3.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="gsd3.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>AGL</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for GSD III are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="gsd3.Resources"><h2 id="_gsd3_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association for Glycogen Storage Disease (AGSD)</b></div><div>PO Box 896</div><div>Durant IA 52747</div><div><b>Phone:</b> 563-514-4022</div><div><b>Email:</b> maryc@agsdus.org</div><div><a href="http://www.agsdus.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.agsdus.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/glycogen-storage-disease-type-iii" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Glycogen storage disease type III</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li></ul></div><div id="gsd3.Molecular_Genetics"><h2 id="_gsd3_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="gsd3.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Glycogen Storage Disease Type III: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26372/table/gsd3.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__gsd3.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_gsd3.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_gsd3.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_gsd3.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_gsd3.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_gsd3.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_gsd3.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_gsd3.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/178" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>AGL</i></a></td><td headers="hd_b_gsd3.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=178" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p21<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_gsd3.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P35573" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Glycogen debranching enzyme</a></td><td headers="hd_b_gsd3.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/AGL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AGL database</a></td><td headers="hd_b_gsd3.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AGL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AGL</a></td><td headers="hd_b_gsd3.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=AGL[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AGL</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="gsd3.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="gsd3.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Glycogen Storage Disease Type III (<a href="/omim/232400,610860" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26372/table/gsd3.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__gsd3.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/232400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">232400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GLYCOGEN STORAGE DISEASE III; GSD3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610860" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610860</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AMYLO-1,6-GLUCOSIDASE, 4-ALPHA-GLUCANOTRANSFERASE; AGL</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>AGL</i> is 85 kb in size with 34 exons (<a href="/entrez/viewer.fcgi?val=NM_000642.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000642.2</a>). <a class="bk_pop" href="#gsd3.REF.bao.1997.389">Bao et al [1997]</a> recognized the presence of six different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> that differ in the 5' end by using several cryptic splice sites upstream of the translation initiation site. This allows the inclusion or removal of exons. Isoform 1 is the generalized form present in liver, muscle, kidney, and lymphoblastoid cells. Isoforms 2, 3, and 4 are present in the muscle and heart. These isoforms are formed as a result of either alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> or a difference in transcription start points. Isoform 1 contains exons 1 and 3; isoforms 2, 3, and 4 start with <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2. Isoforms 1 through 4 all contain exon 3 which includes the normal initiation codon for protein translation. Exons 4-35 are present in isoforms [<a class="bk_pop" href="#gsd3.REF.bao.1996.155">Bao et al 1996</a>, <a class="bk_pop" href="#gsd3.REF.bao.1997.389">Bao et al 1997</a>]. The glycogen binding site is encoded by exons 31 and 32 and the active site is encoded by exons 6, 13, 14, and 15 [<a class="bk_pop" href="#gsd3.REF.elpeleg.1999.363">Elpeleg 1999</a>]. See <a href="/books/NBK26372/#gsd3.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> Most <i>AGL</i> pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a>. Only four alleles (p.Arg864Ter, p.Arg1228Ter, c.3964delT, and c.4349-12A&#x0003e;G) have been found in more than 5% of unselected persons with GSD III [<a class="bk_pop" href="#gsd3.REF.shaiu.2000.16">Shaiu et al 2000</a>].</p><p>Three pathogenic variants (p.Arg864Ter, p.Arg1228Ter, and p.Trp680Ter) account for approximately 28% of the known pathogenic variants in individuals of European origin [<a class="bk_pop" href="#gsd3.REF.demo.2007.492">Demo et al 2007</a>]. See <a class="figpopup" href="/books/NBK26372/table/gsd3.T.selected_agl_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figgsd3Tselectedaglpathogenicvariants" rid-ob="figobgsd3Tselectedaglpathogenicvariants">Table 2</a>.</p><p>Certain populations have common pathogenic variants as a result of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>. For example:</p><ul><li class="half_rhythm"><div>c.1222C&#x0003e;T in persons with GSD III from the Faroe Islands [<a class="bk_pop" href="#gsd3.REF.santer.2001.388">Santer et al 2001</a>]</div></li><li class="half_rhythm"><div>c.4455delT in North African Jewish individuals [<a class="bk_pop" href="#gsd3.REF.parvari.1997.266">Parvari et al 1997</a>]</div></li></ul><div id="gsd3.T.selected_agl_pathogenic_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>AGL</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26372/table/gsd3.T.selected_agl_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__gsd3.T.selected_agl_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.16C&#x0003e;T&#x000a0;<sup>2</sup></td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln6Ter</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_3" rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000642.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000642<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000633.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000633<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.17_18delAG&#x000a0;<sup>2</sup></td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln6HisfsTer20&#x000a0;<sup>3</sup><br />(25*)</td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1222C&#x0003e;T</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg408Ter</td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2039G&#x0003e;A</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp680Ter</td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2590C&#x0003e;T</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg864Ter</td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3682C&#x0003e;T</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1228Ter</td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3965delT</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val1322AlafsTer27&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4349-12A&#x0003e;G&#x000a0;<sup>5</sup><br />(IVS32-12 A&#x0003e;G)</td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4455delT&#x000a0;<sup>3</sup></td><td headers="hd_h_gsd3.T.selected_agl_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser1486ProfsTer18</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="gsd3.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="gsd3.TF.2.2"><p class="no_margin">Associated with the GSD IIIb <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#gsd3.REF.shen.1996.352">Shen et al 1996</a>]</p></div></dd><dt>3. </dt><dd><div id="gsd3.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#gsd3.REF.parvari.1997.266">Parvari et al [1997]</a></p></div></dd><dt>4. </dt><dd><div id="gsd3.TF.2.4"><p class="no_margin">This variant causes a premature stop codon, translating a truncated AGL protein of 1321 <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> amino acids plus 26 novel residues. The protein product lacks 211 amino acid residues, from <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 31, which is one of glycogen binding areas [<a class="bk_pop" href="#gsd3.REF.shaiu.2000.16">Shaiu et al 2000</a>].</p></div></dd><dt>5. </dt><dd><div id="gsd3.TF.2.5"><p class="no_margin">This variant creates a novel <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, such that the 11 <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> nucleotides from the immediate 3&#x02019; end of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 32 are adjoined to the 3' end of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 32 creating a frameshift [<a class="bk_pop" href="#gsd3.REF.shaiu.2000.16">Shaiu et al 2000</a>].</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Glucose molecules forming UDP glucose are added via alpha 1,4 linkages to the matrix for glycogen, called glycogenin. This process is catalyzed by glycogen synthase. When the chain reaches a certain length, "branching enzyme" cleaves off the terminal portion of the chain and attaches it via an alpha 1,6 linkage to the parent chain. This process is repeated over and over again on all the different branches of the chain and the complex glycogen molecules are created.</p><p>When digestion of a meal is complete, insulin levels fall and glucagon is secreted. In a process mediated by the enzyme glycogen phosphorylase, these hormones stimulate cleavage of glucose molecules from the terminal strands of glycogen as glucose-1-phosphate. This process continues until four glucose molecules remain before the alpha 1,6 bond. At this point, the human debranching enzyme with its two distinct catalytic activities comes into play. The 1,4-&#x003b1;-D-glucan 4-&#x003b1;-D-glycosyl transferase component transfers the terminal three glucose molecules to the parent chain and the amylo-1,6-glucosidase component cleaves the alpha 1,6 bond to release free glucose.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> With debranching enzyme deficiency, glycogen cannot be degraded and an abnormal glycogen with branched outer points called "limit dextrin" accumulates.</p><p>Except for the founder variants described previously and some common pathogenic variants, most pathogenic variants are unique. Missense and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, small deletions and insertions, and large intragenic deletions and insertions have been described, many of which produce truncated proteins.</p><p>The <a class="figpopup" href="/books/NBK26372/table/gsd3.T.selected_agl_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figgsd3Tselectedaglpathogenicvariants" rid-ob="figobgsd3Tselectedaglpathogenicvariants">c.4455delT</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the North African Jewish community generates a truncated protein that is about 97% of its length. This proves that the carboxy terminus, downstream of the glycogen binding site, is essential for normal enzyme function [<a class="bk_pop" href="#gsd3.REF.parvari.1997.266">Parvari et al 1997</a>].</p><p>Individuals with GSD IIIb have pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 of one of their <i>AGL</i> alleles. The pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant p.Gln6Ter and the frameshift <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <a class="figpopup" href="/books/NBK26372/table/gsd3.T.selected_agl_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figgsd3Tselectedaglpathogenicvariants" rid-ob="figobgsd3Tselectedaglpathogenicvariants">c.17_18delAG</a> both generate truncated proteins with few amino acids. It is thought that alternative exon or translation initiation in muscle <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> does not require exon 3, thus leading to normal enzyme activity in the muscles of persons with GSD IIIb who have an exon 3 deletion [<a class="bk_pop" href="#gsd3.REF.shen.1996.352">Shen et al 1996</a>, <a class="bk_pop" href="#gsd3.REF.elpeleg.1999.363">Elpeleg 1999</a>].</p></div><div id="gsd3.References"><h2 id="_gsd3_References_">References</h2><div id="gsd3.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.bao.1996.155">Bao Y, Dawson TL Jr, Chen YT. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region. <span><span class="ref-journal">Genomics. </span>1996;<span class="ref-vol">38</span>:155–65.</span> [<a href="/pubmed/8954797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8954797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.bao.1997.389">Bao Y, Yang BZ, Dawson TL Jr, Chen YT. Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: identification of multiple tissue-specific isoforms. <span><span class="ref-journal">Gene. </span>1997;<span class="ref-vol">197</span>:389–98.</span> [<a href="/pubmed/9332391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9332391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.bernier.2008.729">Bernier AV, Sentner CP, Correia CE, Theriaque DW, Shuster JJ, Smit GP, Weinstein DA. Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span>:729–32.</span> [<a href="/pmc/articles/PMC3832627/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3832627</span></a>] [<a href="/pubmed/18709545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18709545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.chen.2001">Chen YT. Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Disease.</em> 8 ed. New York, NY: McGraw Hill; 2001:1521-51.</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.cosme.2005.622">Cosme A, Montalvo I, Sanchez J, Ojeda E, Torrado J, Zapata E, Bujanda L, Gutierrez A, Arenas I. Type III glycogen storage disease associated with hepatocellular carcinoma. <span><span class="ref-journal">Gastroenterol Hepatol. </span>2005;<span class="ref-vol">28</span>:622–5.</span> [<a href="/pubmed/16373012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16373012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.dagli.2009.s103">Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. <span><span class="ref-journal">J Inherit Metab Dis. </span>2009;<span class="ref-vol">32</span> Suppl 1:S103–6.</span> [<a href="/pmc/articles/PMC3808093/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3808093</span></a>] [<a href="/pubmed/19322675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19322675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.davis.2008.137">Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. <span><span class="ref-journal">Pediatr Transplant. </span>2008;<span class="ref-vol">12</span>:137–45.</span> [<a href="/pubmed/18307661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18307661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.demo.2007.492">Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, Chen YT, Kishnani PS. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? <span><span class="ref-journal">J Hepatol. </span>2007;<span class="ref-vol">46</span>:492–8.</span> [<a href="/pmc/articles/PMC2683272/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2683272</span></a>] [<a href="/pubmed/17196294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17196294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.elpeleg.1999.363">Elpeleg ON. The molecular background of glycogen metabolism disorders. <span><span class="ref-journal">J Pediatr Endocrinol Metab. </span>1999;<span class="ref-vol">12</span>:363–79.</span> [<a href="/pubmed/10821216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10821216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.endo.2009.1233">Endo Y, Fateen E, El Shabrawy M, Aoyama Y, Ebara T, Murase T, Podskarbi T, Shin YS, Okubo M. Egyptian glycogen storage disease type III - identification of six novel AGL mutations, including a large 1.5 kb deletion and a missense mutation p.L620P with subtype IIId. <span><span class="ref-journal">Clin Chem Lab Med. </span>2009;<span class="ref-vol">47</span>:1233–8.</span> [<a href="/pubmed/19754354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19754354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.endo.2006.958">Endo Y, Horinishi A, Vorgerd M, Aoyama Y, Ebara T, Murase T, Odawara M, Podskarbi T, Shin YS, Okubo M. Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey. <span><span class="ref-journal">J Hum Genet. </span>2006;<span class="ref-vol">51</span>:958–63.</span> [<a href="/pubmed/17047887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17047887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.goldstein.2010.424">Goldstein JL, Austin SL, Boyette K, Kanaly A, Veerapandiyan A, Rehder C, Kishnani PS, Bali DS. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. <span><span class="ref-journal">Genet Med. </span>2010;<span class="ref-vol">12</span>:424–30.</span> [<a href="/pubmed/20648714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.hobsonwebb.2010.440">Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS. The electrodiagnostic characteristics of Glycogen Storage Disease Type III. <span><span class="ref-journal">Genet Med. </span>2010;<span class="ref-vol">12</span>:440–5.</span> [<a href="/pubmed/20071996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20071996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.illingworth.1952.653">Illingworth B, Cori GT. Structure of glycogens and amylopectins. III. Normal and abnormal human glycogen. <span><span class="ref-journal">J Biol Chem. </span>1952;<span class="ref-vol">199</span>:653–60.</span> [<a href="/pubmed/13022672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13022672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.lee.1997.834">Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV. Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. <span><span class="ref-journal">Am J Cardiol. </span>1997;<span class="ref-vol">79</span>:834–8.</span> [<a href="/pubmed/9070576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9070576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.lu.2016.641">Lu C, Qiu Z, Sun M, Wang W, Wei M, Zhang X. Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations. <span><span class="ref-journal">J Hum Genet. </span>2016;<span class="ref-vol">61</span>:641–5.</span> [<a href="/pubmed/26984562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26984562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.lucchiari.2007.72">Lucchiari S, Santoro D, Pagliarani S, Comi GP. Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. <span><span class="ref-journal">Acta Myol. </span>2007;<span class="ref-vol">26</span>:72–4.</span> [<a href="/pmc/articles/PMC2949315/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2949315</span></a>] [<a href="/pubmed/17915576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17915576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.melis.2016.79">Melis D, Rossi A, Pivonello R, Del Puente A, Pivonello C, Cangemi G, Negri M, Colao A, Andria G, Parenti G. Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. <span><span class="ref-journal">Bone. </span>2016;<span class="ref-vol">86</span>:79–85.</span> [<a href="/pubmed/26924264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26924264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.mundy.2008.418">Mundy HR, Williams JE, Lee PJ, Fewtrell MS. Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span>:418–23.</span> [<a href="/pubmed/18392743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18392743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.parvari.1997.266">Parvari R, Moses S, Shen J, Hershkovitz E, Lerner A, Chen YT. A single-base deletion in the 3'-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients. <span><span class="ref-journal">Eur J Hum Genet. </span>1997;<span class="ref-vol">5</span>:266–70.</span> [<a href="/pubmed/9412782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9412782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.preisler.2015.1767">Preisler N, Lafor&#x000ea;t P, Madsen KL, Prahm KP, Hedermann G, Vissing CR, Galbo H, Vissing J. Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">84</span>:1767–71.</span> [<a href="/pubmed/25832663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25832663</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.ross.2015.137">Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, Porras LY, Mathew JT, Dambska M, Weinstein DA. Safety and efficacy of long-term use of extended release cornstarch therapy for glycogen storage disease types 0, III, VI, and IX. <span><span class="ref-journal">J Nutr Ther. </span>2015;<span class="ref-vol">4</span>:137–42.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.rousseaunepton.2015.e68">Rousseau-Nepton I, Okubo M, Grabs R., FORGE Canada Consortium.  Mitchell J, Polychronakos C, Rodd C. A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series. <span><span class="ref-journal">CMAJ. </span>2015;<span class="ref-vol">187</span>:E68–73.</span> [<a href="/pmc/articles/PMC4312169/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4312169</span></a>] [<a href="/pubmed/25602008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25602008</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.santer.2001.388">Santer R, Kinner M, Steuerwald U, Kjaergaard S, Skovby F, Simonsen H, Shaiu WL, Chen YT, Schneppenheim R, Schaub J. Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. <span><span class="ref-journal">Eur J Hum Genet. </span>2001;<span class="ref-vol">9</span>:388–91.</span> [<a href="/pubmed/11378828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11378828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.seigel.2008.587">Seigel J, Weinstein DA, Hillman R, Colbert B, Matthews B, Bachrach B. Glycogen storage disease type IIIa presenting as non-ketotic hypoglycemia: use of a newly approved commercially available mutation analysis to non-invasively confirm the diagnosis. <span><span class="ref-journal">J Pediatr Endocrinol Metab. </span>2008;<span class="ref-vol">21</span>:587–90.</span> [<a href="/pubmed/18717245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18717245</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.sentner.2012.13">Sentner CP, Caliskan K, Vletter WB, Smit GP. Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type IIIa patient. <span><span class="ref-journal">JIMD Rep. </span>2012;<span class="ref-vol">5</span>:13–6.</span> [<a href="/pmc/articles/PMC3509915/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509915</span></a>] [<a href="/pubmed/23430911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.sentner.2016.697">Sentner CP, Hoogeveen IJ, Weinstein DA, Santer R, Murphy E, McKiernan PJ, Steuerwald U, Beauchamp NJ, Taybert J, Lafor&#x000ea;t P, Petit FM, Hubert A, Labrune P, Smit GP, Derks TG. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. <span><span class="ref-journal">J Inherit Metab Dis. </span>2016;<span class="ref-vol">39</span>:697–704.</span> [<a href="/pmc/articles/PMC4987401/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4987401</span></a>] [<a href="/pubmed/27106217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27106217</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.shaiu.2000.16">Shaiu WL, Kishnani PS, Shen J, Liu HM, Chen YT. Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease. <span><span class="ref-journal">Mol Genet Metab. </span>2000;<span class="ref-vol">69</span>:16–23.</span> [<a href="/pubmed/10655153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10655153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.shen.1996.352">Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. <span><span class="ref-journal">J Clin Invest. </span>1996;<span class="ref-vol">98</span>:352–7.</span> [<a href="/pmc/articles/PMC507437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC507437</span></a>] [<a href="/pubmed/8755644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8755644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.siciliano.2000.80">Siciliano M, De Candia E, Ballarin S, Vecchio FM, Servidei S, Annese R, Landolfi R, Rossi L. Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. <span><span class="ref-journal">J Clin Gastroenterol. </span>2000;<span class="ref-vol">31</span>:80–2.</span> [<a href="/pubmed/10914784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10914784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.slonim.1984.906">Slonim AE, Coleman RA, Moses WS. Myopathy and growth failure in debrancher deficiency: improvement with high-protein nocturnal enteral therapy. <span><span class="ref-journal">J Pediatr. </span>1984;<span class="ref-vol">105</span>:906–11.</span> [<a href="/pubmed/6438290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6438290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.slonim.1982.420">Slonim AE, Weisberg C, Benke P, Evans OB, Burr IM. Reversal of debrancher deficiency myopathy by the use of high-protein nutrition. <span><span class="ref-journal">Ann Neurol. </span>1982;<span class="ref-vol">11</span>:420–2.</span> [<a href="/pubmed/7049057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7049057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.valayannopoulos.2011.638">Valayannopoulos V, Bajolle F, Arnoux JB, Dubois S, Sannier N, Baussan C, Petit F, Labrune P, Rabier D, Ottolenghi C, Vassault A, Broissand C, Bonnet D, de Lonlay P. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D,L-3-hydroxybutyrate, ketogenic and high protein diet. <span><span class="ref-journal">Pediatr Res. </span>2011;<span class="ref-vol">70</span>:638–41.</span> [<a href="/pubmed/21857385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21857385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.wary.2010.548">Wary C, Nadaj-Pakleza A, Lafor&#x000ea;t P, Claeys KG, Carlier R, Monnet A, Fleury S, Baligand C, Eymard B, Labrune P, Carlier PG. Investigating glycogenosis type III patients with multi-parametric functional NMR imaging and spectroscopy. <span><span class="ref-journal">Neuromuscul Disord. </span>2010;2010;<span class="ref-vol">20</span>:548–58.</span> [<a href="/pubmed/20620060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20620060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="gsd3.REF.wolfsdorf.2003.95">Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. <span><span class="ref-journal">Rev Endocr Metab Disord. </span>2003;<span class="ref-vol">4</span>:95–102.</span> [<a href="/pubmed/12618563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12618563</span></a>]</div></li></ul></div></div><div id="gsd3.Chapter_Notes"><h2 id="_gsd3_Chapter_Notes_">Chapter Notes</h2><div id="gsd3.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>29 December 2016 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 September 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 March 2011 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/targeted-mutation-analysis/">targeted mutation analysis</a> no longer listed in the GeneTests Laboratory Directory as clinically available</div></li><li class="half_rhythm"><div>21 October 2010 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available for <i>AGL</i></div></li><li class="half_rhythm"><div>3 March 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>5 November 2009 (daw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK26372</span><span class="label">PMID: <a href="/pubmed/20301788" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301788</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/gsd1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/gsd4/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK26372&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK26372/?report=reader">PubReader</a></li><li><a href="/books/NBK26372/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK26372" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK26372" style="display:none" title="Cite this Page"><div class="bk_tt">Dagli A, Sentner CP, Weinstein DA. Glycogen Storage Disease Type III. 2010 Mar 9 [Updated 2016 Dec 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK26372/pdf/Bookshelf_NBK26372.pdf">PDF version of this page</a> (451K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#gsd3.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#gsd3.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#gsd3.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#gsd3.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#gsd3.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#gsd3.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#gsd3.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#gsd3.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#gsd3.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#gsd3.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#gsd3.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=178[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AGL</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK26372+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1952942" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1952942" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1952942" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1952942" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301760" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type VI</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type VI<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Labrador E, Weinstein DA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23285490" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type IV</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type IV<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Magoulas PL, El-Hattab AW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21634085" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Herbert M, Goldstein JL, Rehder C, Austin S, Kishnani PS, Bali DS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301489" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bali DS, Chen YT, Austin S, Goldstein JL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31804789" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fructose-1,6-Bisphosphatase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fructose-1,6-Bisphosphatase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bijarnia-Mahay S, Bhatia S, Arora V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301788" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301788" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc90f039a66ee2bac36cc8">Glycogen Storage Disease Type III - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Glycogen Storage Disease Type III - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:14:24-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8ADE04DFC88231000000000443022B&amp;ncbi_session=CE8ADE04DFC90EF1_1091SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK26372%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK26372&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK26372/&amp;ncbi_pagename=Glycogen Storage Disease Type III - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8ADE04DFC90EF1_1091SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>